tradingkey.logo

Prophase Labs Inc

PRPH
View Detailed Chart

0.388USD

-0.030-7.21%
Close 09/19, 16:00ETQuotes delayed by 15 min
16.10MMarket Cap
LossP/E TTM

Prophase Labs Inc

0.388

-0.030-7.21%
Intraday
1m
30m
1h
D
W
M
D

Today

-7.21%

5 Days

-10.59%

1 Month

+24.03%

6 Months

-2.83%

Year to Date

-48.80%

1 Year

-84.56%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The company shows very weak stock market performance, in line with its fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
63 / 72
Overall Ranking
508 / 4720
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 0 analysts
--
Current Rating
16.000
Target Price
+5111.73%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Growing
The company is in a growing phase, with the latest annual income totaling USD 6.77M.
Fairly Valued
The company’s latest PE is -0.20, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 7.80M shares, increasing 6.31% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 408.27K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 4.02.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

ProPhase Labs, Inc. is a biopharma, genomics, and diagnostics company. The Company provides whole genome sequencing solutions, while developing potential diagnostics and therapeutics in the fight against cancer. This includes a potentially life-saving cancer test focused on early detection of esophageal cancer and potential breakthrough cancer therapeutics with novel mechanisms of action. Its segments include diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter consumer healthcare products and dietary supplements in the United States and also provides personal genomics products and services. Its CLIA labs and diagnostic technology provide wellness solutions.
Ticker SymbolPRPH
CompanyProphase Labs Inc
CEOMr. Ted William Karkus
Websitehttps://www.prophaselabs.com/
KeyAI